Table 3.

Characteristics of Fenbendazole (FEN) and Rapamycin (RAPA) Encapsulated in Various Polymers (n = 3)

Formulation	Polymer Category	Amount of Polymer Used (mg)	Amount of FEN Used (mg)	Amount of RAPA Used (mg)	FEN Encapsulation Efficiency (EE %)	RAPA Encapsulation Efficiency (EE %)	FEN Drug Loading (DL %)	RAPA Drug Loading (DL %)	Particle Size (nm)	Poly-Dispersity Index (PDI)	Zeta Potential (mV)
FEN:RAPA 1:1	mPEG-b-PCL	100	1	3	77.0 ± 4.25	86.4 ± 0.79	0.76 ± 0.04	2.52 ± 0.02	33.6 ± 0.23	0.11 ± 0.01	−3.88 ± 0.60
		100	2	6	39.4 ± 0.57	83.4 ± 2.52	0.77 ± 0.01	4.72 ± 0.14	34.4 ± 1.04	0.11 ± 0.01	−4.48 ± 0.61
	mPEG-b-PLA	100	1	3	58.2 ± 7.02	85.0 ± 10.1	0.58 ± 0.07	2.48 ± 0.30	264 ± 88.0	0.35 ± 0.04	−4.95 ± 0.44
		100	2	6	34.6 ± 1.56	84.3 ± 3.91	0.68 ± 0.03	4.77 ± 0.22	131 ± 25.5	0.39 ± 0.03	−6.23 ± 1.53
	Soluplus®	100	1	3	79.2 ± 0.58	84.7 ± 5.14	0.78 ± 0.01	2.47 ± 0.15	58.9 ± 0.29	0.04 ± 0.01	−2.88 ± 0.18
		100	2	6	42.6 ± 2.77	85.9 ± 5.45	0.83 ± 0.05	4.86 ± 0.31	59.6 ± 0.56	0.03 ± 0.01	−3.37 ± 0.75
FEN:RAPA 1:2	mPEG-b-PCL	100	0.5	3	72.1 ± 1.22	80.0 ± 2.20	0.36 ± 0.01	2.33 ± 0.06	38.2 ± 3.37	0.23 ± 0.03	−1.82 ± 0.80
		50	1	6	57.3 ± 1.94	85.4 ± 0.75	1.12 ± 0.04	10.0 ± 0.09	34.6 ± 0.29	0.14 ± 0.03	−5.2 ± 2.23
		100	1	6	90.8 ± 5.12	90.1 ± 5.11	0.90 ± 0.05	5.10 ± 0.29	33.2 ± 0.62	0.09 ± 0.00	−4.75 ± 0.53
		150	1	6	77.2 ± 3.07	83.8 ± 3.11	0.51 ± 0.02	3.22 ± 0.12	40.5 ± 4.34	0.25 ± 0.03	2.23 ± 2.41
	mPEG-b-PLA	100	0.5	3	65.4 ± 0.59	82.7 ± 0.27	0.33 ± 0.00	2.41 ± 0.01	187 ± 8.37	0.37 ± 0.03	−8.02 ± 0.43
		100	1	6	92.0 ± 3.71	95.3 ± 3.71	0.91 ± 0.04	5.39 ± 0.21	155 ± 12.4	0.39 ± 0.02	−5.67 ± 0.60
	Soluplus®	100	0.5	3	58.9 ± 1.63	73.6 ± 2.62	0.29 ± 0.01	2.14 ± 0.08	60.3 ± 0.33	0.05 ± 0.02	−4.75 ± 1.29
		100	1	6	73.3 ± 1.17	83.9 ± 3.49	0.73 ± 0.01	4.75 ± 0.20	58.9 ± 0.21	0.04 ± 0.01	−4.87 ± 1.97